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                                       INTRODUCTION
Cancer cervix is the second commonest malignancy among women globally, with 
over 4,50,000 cases detected annually and accounting for almost 2,10,000 deaths per 
year.  During  the  past  5  decades  the  incidence  of  invasive  cervical  carcinoma  has 
dropped  dramatically  which  is  attributed  to  the  development  of  effective  screening 
techniques for identification of pre-invasive lesions.The scenario, however, is still grim 
in the developing world wherein a combination of inadequate screening facilities, social 
stigma and ignorance contribute to patient presenting with locally advanced disease.
NATURAL HISTORY
INCIDENCE
The incidence of cancer cervix varies from country to country and from race to 
race. The highest incidence rates are reported from Asia, South America and Africa. In 
India,  cancer  cervix   constitutes  20  –  50% of  all  cancers  detected  in  women.  The 
incidence of cancer cervix among the various cancer registries of the country ranges 
from 19 – 44 per 1,00,000 women (mean 31.4 per 1,00,000 women). In Chennai as per 
MMTR (Madras Metropolitan Tumor Registry) statistics the incidence of cancer cervix 
is 26.9 / 1,00,000 women which accounts for 21.11% of the total cancer incidence.
PREDISPOSING FACTORS:
The major  predisposing factors of cancer cervix include poor physical as 
well as sexual hygiene.
1. Female sexual behavior
a) Sexual intercourse-This is the major prerequisite for the development of 
squamous cell carcinoma of cervix.
b) Age at first coitus – Women who start  their sexual life at an early age 
particularly before 18 years are at higher risk (1.4 to 1.9 times increased risk) of 
developing cancer cervix.
c) Multiple sexual partners – Cancer cervix patients usually give a history of 
multiple sexual partners. The risk is doubled for women with 6 sexual partners.
d) Parity – Risk factors related to parity include first child birth at an early 
age and multiparity.
2. Male sexual behavior (high risk male) – 
High risk male sexual habits, the presence of which is associated with a higher 
incidence of cancer cervix in their spouses are:-
a) Sexual promiscuity: >3 extra marital partners
b) History of sexually transmitted disease
c) Poor penile hygiene: Causative role of cigarette smoking in male and the 
protective effect of male circumcision are controversial.
3. Lower socio-economic group 
 Women from a lower socio-economic group have a higher incidence (about 3 
fold) of cervical malignancy due to early marriage, early onset of sexual life and 
lack of genital hygiene.
4. Viral etiology 
a) HPV (Human  Papilloma  Virus)  –  Among  various  agents,  the  HPV  virus  is 
considered to be the most likely candidate for etiological responsibility. Infection 
with HPV serotypes 16 & 18 are highly prevalent  in CIN-II,  III  and invasive 
cancer cervix. HPV exerts its effect by P-53 gene suppression and inhibition of 
cell mediated immunity.
b) HIV (Human immunodeficiency virus) – Women who are HIV positive have a 10 
fold risk of cervical cancer in comparison with matched controls. Prevalence of 
cancer cervix in HIV positive patients below the age of 50 years is 19%.
c) HSV (Herpes  simplex  virus)  –  There  is  much  data  suggesting  an  association 
between cancer cervix and HSV but no conclusive evidence is available.
Smoking – Smoking appears to double the risk of developing cervical cancer. Apart 
from the above mentioned factors, higher risk of adenocarcinoma of cervix is associated 
with obesity, diabetes, hypertension and prenatal exposure to Diethyl stilbesterol (clear 
cell adenocarcinoma).
FIGO Staging: The primary tumor (T) is staged in the following way:
Stage 0 - Carcinoma in situ( Preinvasive carcinoma). 
Stage I - Cervical carcinoma confined to uterus. 
Stage I A -Invasive carcinoma diagnosed by microscopy with stromal invasion is not > 
5  mm in depth and 7 mm wide. 
Stage I A 1 -Stromal invasion is <3 mm in depth and <7 mm in width. This is also called 
micro invasive carcinoma. 
Stage I A 2 -Stromal invasion 3 mm -5 mm in depth and <7 mm in width. 
Stage I B -  Visible tumor only on the cervix or by microscopy is >5 mm in depth and 7 
mm   wide. 
Stage I B1 - Visible tumor is ≤ 4 cm (1.6 in.). 
Stage I B2 - Visible tumor is > 4 cm (1.6 in.) in size.
Stage II - Beyond the uterus but not the pelvic wall or the lower third of the vagina. 
Stage IIA - Tumor does not involve the parametrium . 
Stage IIB -Tumor extends  into the parametrium not up to the side wall .
Stage III -The tumor extends to the pelvic wall or involves the lower third of the vagina 
or causes an obstructed or a nonfunctioning kidney. 
Stage IIIA - Tumor involves lower third of vagina but no extension into the pelvic wall. 
Stage  IIIB  - Tumor  extends  to  pelvic  wall  or  causes  an  obstructed  kidney  or 
nonfunctioning kidney.
Stage  IVA  - Tumor  invades  the  lining  of  the  bladder  or  rectum,  or  
extends beyond the pelvis. 
Stage IV B – Distant metastasis.  
STAGE GROUPING
0 Tis N0 M0
I T1 N0 M0
IA T1a N0 M0
IA1 T1a1 N0 M0
IA2 T1a2 N0 M0
IB T1b N0 M0
IB1 T1b1 N0 M0
IB2 T1b2 N0 M0
II T2 N0 M0
IIA T2a N0 M0
IIB T2b N0 M0
III T3 N0 M0
IIIA T3a N0 M0
IIIB T1,T2,T3a
T3b
N1
AnyN
M0
IVA T4 AnyN M0
IVB AnyT AnyN M1
PROGNOSTIC FACTORS
1. Stage of the disease – Prognosis in cervical cancer worsens with advancing 
stage of the disease. The size of the primary tumor (disease bulk) and the depth of 
invasion into the cervix were found to be associated with increased recurrence 
rate and poor survival.
2. Pelvic  lymph  node  involvement –  Several  researchers  reported  increased 
recurrence rates and decreased survival with lymphovascular invasion and  nodal 
metastasis.
3. Parametrial involvement – The extent of parametrial involvement was again 
found to correlate adversely with survival.
Extent of parametrial involvement and prognosis
Stage Extent of parametrial disease
Survival
(5 yrs)
II B  Unilateral involvement 70%
II B  Bilateral involvement 58%
III B Unilateral involvement 48%
III B Bilateral involvement 28%
5) Histology – Fuller et al. reported increased recurrence rates with patients having 
adenocarcinoma in comparison with those having squamous histology. 
6) Grade – Fuller et al. found that  the higher histological grade was associated with 
an increased incidence of recurrence.
7) Age – Age at the time of diagnosis was found to have no effect on prognosis, 
although some researchers observed a decrease in survival for very young patients 
and for older patients.
8) Ploidy – It was found that there were no statistically significant differences in 
recurrence rates for patients with diploid and aneuploid tumors. More relapses 
were noted with tumor S-phase fraction greater than 20%.
9) Overall treatment time – Perez  et al. have reported that the pelvic control and 
disease  free  survival  rates  are  lower  for  those  patients  whose  treatment  time 
exceeds 7 weeks.
10) Patient  factors –  Mandelblatt  et  al..  have shown that  anemia  (Hb <10gm%), 
platelet count, socio-economic status and smoking were associated with increased 
pelvic recurrences and decreased survival.
11)
OVERVIEW OF TREATMENT POLICY IN CANCER CERVIX:
All  the  three  standard  modalities  of  treatment  namely  surgery,  radiation  and 
chemotherapy have stamped their role in the different stages of the disease. 
Primary Treatment
              After careful clinical evaluation and staging, the primary treatment of early-
stage cervical cancer is either surgery or radiation therapy. A randomized Italian study 
compared RT alone versus radical hysterectomy and lymph node dissection. This study 
used adjuvant RT after surgery for women with surgical stage pT2b (which corresponds 
to  FIGO stage  IIB)  or  more  extensive  disease.  The NCCN panel  reached a  general 
agreement, based on the results of five randomized clinical trials, that RT and concurrent 
cisplatin-based chemotherapy (either cisplatin alone or cisplatin/5-fluorouracil [5-FU]) 
should be the treatment of choice for stages IIB, IIIA, IIIB, and IVA disease.
             Surgery is typically reserved for lower-stage disease and smaller lesions, such as 
stage 1A and 1B1 and non bulky IIA. Of interest, the French National Federation of 
Cancer  Centers  have  also  updated  their  guidelines  (Standards,  Options,  and 
Recommendations  [SOR]  project)  by  stating  that  chemoradiotherapy  should  be  the 
standard for women with  bulky cervical cancer. Extrafascial Type I hysterectomy is 
recommended for patients with clinical stage IA1 disease; another option is modified 
radical hysterectomy with pelvic lymph node dissection if lymphovascular invasion is 
present. However, if the patient is medically inoperable or if fertility is desired, patients 
with negative margins from cone biopsy could undergo observation. Stage IA2 tumors 
can  be  treated  with  radical  hysterectomy and  pelvic  lymph node dissection  with  or 
without para-aortic lymph node sampling. Brachytherapy with pelvic radiation (point A 
dose: 75-80 Gy) is another treatment option. These doses are recommended for most 
patients based on summation of conventional external-beam fractionation and low-dose-
rate (40-60 cGy/h) brachytherapy equivalents. Treatment should be modified based on 
normal  tissue  tolerance.  For  patients  who  desire  fertility  preservation,  radical 
trachelectomy and lymph node dissection are recommended. 
             Among panel members, there was some disagreement about the primary 
approach for stage 1B2/IIA disease. Patients with stage IB1or non bulky IIA tumors can 
be  treated  effectively  with  radical  hysterectomy  plus  bilateral  pelvic  lymph  node 
dissection with para-aortic node sampling or  with combined pelvic radiotherapy and 
brachytherapy. Substantial discussion occurred about the optimal management of stage 
IB2 and bulky IIA (greater than 4 cm) disease. For patients with clinical stage IB2 or IIA 
tumors  (greater  than  4  cm)  who  are  treated  with  radiation,  concurrent  cisplatin-
containing chemotherapy has been shown to significantly improve patient survival. The 
addition  of  concurrent  chemoradiation  significantly  improves  progression-free  and 
overall  survival  for  high-risk  patients  with  early-stage  disease  (those  with  positive 
lymph  nodes,  parametrial  extension,  and/or  positive  margins)  who  undergo  radical 
hysterectomy and pelvic lymphadenectomy. For stage IB2 or IIA tumors (greater than 4 
cm),  the  panel  disagreed  about  recommending  adjuvant  hysterectomy  for  patients 
undergoing primary chemoradiation.
              The EORTC is currently conducting a phase III randomized trial (EORTC 
55994)  of  neoadjuvant  cisplatin  based  chemotherapy  followed  by  surgery  compared 
with RT plus chemotherapy in patients with stage IB or II cervical cancer. For patients 
with more advanced tumors who are undergoing primary chemoradiation, the volume of 
RT is critical and is guided by assessment of nodal involvement in the pelvis and para-
aortic  nodes.  Imaging  studies  (CT or  MRI  and/or  PET scan)  are  recommended  for 
selected bulky stage IB2 or higher disease. 
             However, fine-needle aspiration (FNA) is needed to confirm suspicious lymph 
nodes seen on radiologic imaging. Surgical staging (i.e., extra peritoneal or laparoscopic 
lymph node dissection)  is  also recommended for  these patients.  If  node sampling is 
performed and indicates positive findings, intraoperative radiotherapy (IORT) should be 
considered for bulky residual nodes. For patients without nodal disease or with disease 
limited  to  the  pelvis  only  by  surgical  staging,  treatment  consists  of  pelvic  RT with 
concurrent chemotherapy.  However, for patients with positive para-aortic and pelvic 
lymph nodes, retroperitoneal lymph node dissection should be considered followed by 
extended-field RT, cisplatin-containing chemotherapy, and brachytherapy. Patients with 
positive para-aortic lymph nodes who are positive for distant metastases are treated with 
systemic chemotherapy  and individualized RT.
Adjuvant treatment
                Adjuvant treatment is indicated after radical hysterectomy depending on  
surgical findings and disease stage. For small-volume tumors (4 cm or less) in stage IA2, 
IB1, or IIA, if lymph nodes are found negative in the surgery, patients should undergo 
close observation or receive pelvic radiation if deep stromal invasion or LVSI is present. 
             Adjuvant pelvic RT alone versus no further therapy was tested in a randomized  
trial  (Gynecologic  Oncology  Group  [GOG]  92)  of  selected  patients  with  stage  IB 
carcinoma of the cervix after hysterectomy and pelvic lymphadenectomy. Patients were 
eligible for this trial after radical hysterectomy and pelvic lymphadenectomy if they had 
at least two of the following risk factors: (1) greater than one-third stromal invasion; (2) 
capillary lymphatic space involvement; or (3) large cervical tumor diameters. Patients 
with positive lymph nodes or involved surgical margins were excluded. A statistically 
significant  decrease  in  recurrence  was  found  in  the  RT arm compared  with  the  no 
additional treatment arm (15% versus 28%). Life-table analysis indicated a statistically 
significant (47%) reduction in risk of recurrence (relative risk = 0.53;= .008) in the RT 
group. At 2 years, the recurrence-free rates were 88% for the RT group versus 79% for 
the no further  treatment group. Patients  with positive pelvic nodes,  positive surgical 
margin, or positive parametrium should be treated with postoperative pelvic radiation 
with  concurrent  chemotherapy.vaginal  brachytherapy  is  also  indicated  if  the  vaginal 
margin is positive.  As previously noted,  Intergroup Trial  0107 showed a statistically 
significant benefit of adjuvant pelvic radiation with 5-FU and cisplatin in the treatment 
of patients with stage IA2, IB, or IIA disease who had positive lymph nodes, positive 
margins, or microscopic parametrial involvement found at surgery. 
                 If para-aortic lymph nodes are found positive during surgical staging, patients  
must undergo further screening with chest CT or PET scan. In women who are positive 
for distant metastases, biopsy of suspicious areas should be considered as indicated. If 
all findings are negative, patients should be treated with para aortic lymph node RT, 
concurrent  chemotherapy,  and  pelvic  RT  with  or  without  brachytherapy.  However, 
patients  with  positive  results  should  be  treated  with  systemic  chemotherapy  and 
individualized radiotherapy. 
 Surveillance
               Because no definitive study or uniform agreement exists on the best method for 
post-treatment surveillance for cervical cancer, the NCCN panel combined the practice 
patterns of member institutions and issued consensus recommendations. Patient follow-
up includes interval history and physical examination, with a Pap test every 3 months for 
1 year, every 4 months for the second year, every 6 months for another 3 years, and then 
annually. Chest radiographs can be done annually. Many of the tests remain optional, 
such as semiannual complete blood counts, blood urea nitrogen, and serum creatinine 
determinations. Patients with persistent or recurrent disease need to be evaluated using 
imaging studies (such as pelvic/abdominal/chest CT/PET scan) and surgical exploration 
in selected cases followed by salvage therapy.
                Use of a vaginal dilator is suggested after RT for women who wish to remain  
sexually active.  Patients  with a  localized recurrence of  cervical  cancer  after  surgery 
should be evaluated for salvage radiotherapy. Salvage rates of approximately 40% have 
been reported in such situations. For patients who experience pelvic recurrences with no 
prior RT or who experience recurrences outside of the previously treated field, salvage 
therapy includes definitive pelvic radiation and platinum based chemotherapy with or 
without brachytherapy.
Salvage therapy 
            Patients with central pelvic recurrent disease after RT should be evaluated for  
pelvic  exenteration,  with  or  without  IORT;  in  carefully  selected  patients  with  small 
lesions  (less  than  2  cm),  options  include   radical  hysterectomy  or  brachytherapy. 
Surgical mortality is generally 5% or lower, with survival rates between 20% and 60%. 
Concomitant  measures  with  such  radical  procedures  include  adequate  rehabilitation 
programmes  dealing  with  the  psychosocial  and  psychosexual  consequences  of  the 
operation  as  well  as  reconstructive  procedures.  Women  with  recurrence  after  pelvic 
exenteration should be treated with platinum-based chemotherapy, best supportive care, 
or be enrolled in a clinical trial.  Patients with isolated recurrences may benefit from 
surgical  resection  with  or  without  IORT,  tumor-directed  RT  with  concurrent 
chemotherapy, or chemotherapy. Those with noncentral disease should be treated with 
pelvic exenteration or resection with IORT for close or positive margins, tumor-directed 
RT with or without chemotherapy, platinum-based chemotherapy, best supportive care, 
or participation in a clinical trial.
Systemic therapy and palliation
              Patients with extra pelvic or para-aortic recurrence(s) at multiple sites or with 
unresectable recurrence(s) should be treated with platinum doublet-based chemotherapy 
or  best  supportive  care.  Isolated  site  recurrence(s)  can  be  managed  with  surgical 
resection with or without IORT, tumor-directed RT with concurrent chemotherapy, or 
chemotherapy.  Patients  may  then  undergo  RT  (optional),  adjuvant  chemotherapy 
(optional), or best supportive care. Occasionally, patients may benefit from radiotherapy 
to a localized recurrence(s). Generally, these areas would be  bone metastases, or painful 
para-aortic nodal recurrences. Clearly, pain relief of a transient nature may be achieved 
in responders to chemotherapy. Chemotherapy has a limited role in prolonging survival 
or  improving  quality  of  life  and  is  recommended  for  patients  with  extra  pelvic 
metastases or recurrent disease who are not candidates for RT or exenterative surgery. 
                 Cisplatin is generally regarded as the most active agent and is recommended  
as first-line chemotherapy in recurrent or metastatic cervical cancer; reported response 
rates are approximately 20% to 30%, with an occasional complete response. However, 
combination regimens are preferred if cisplatin was previously used as a radio sensitizer. 
Carboplatin,  topotecan,  and  paclitaxel  have  also  been  reported  to  be  tolerable  and 
efficacious.  Complete  responses  were  also  observed  with  topotecan  and  paclitaxel; 
however,  topotecan  is  associated  with  more  toxicity  than  carboplatin  or  paclitaxel. 
Therefore, palliation with single-agent cisplatin, carboplatin, paclitaxel, or topotecan is a 
reasonable  approach  in  patients  with  recurrent  disease  not  amenable  to  surgical  or 
radiotherapeutic approaches. Other agents reported to show a partial response include 
ifosfamide, vinorelbine, irinotecan, epirubicin, mitomycin, and 5-FU. A phase II study 
evaluating the effectiveness of docetaxel in patients who have persistent or recurrent 
cervical cancer is ongoing (GOG-0127S).  Cisplatin-based combination chemotherapy 
regimens  such  as  cisplatin/paclitaxel  and  cisplatin/topotecan  have  been  extensively 
investigated in clinical studies. 
Present study
           This prospective non randomized study was performed to evaluate the role of 
radical surgery in stage II B patients after external beam RT to establish surgery as an 
useful modality of treatment in prevention of late recurrences and to avoid intracavity 
RT  and  its  long  term  complications  like  adhesive  vaginitis,  bladder  and  rectal 
morbidities. We then assessed the impact of surgery on local control and survival of the 
patients.     
                                   II. LITERATURE REVIEW
               Radical hysterectomy is recognized as one of the best treatment methods for 
stage IB-II invasive uterine cervical carcinoma, and postoperative radiation therapy is 
preferred for patients with risk factors such as lymph node metastasis, positive surgical 
margins, and deep stromal invasion. When patients recurred, the most predominant site 
was the pelvis; distant recurrence alone was rare. In patients with close vaginal margins, 
Estape  et al. reported that the 5-year survival rate of patients treated by postoperative 
radiation therapy was 81.3% and that of patients not treated by postoperative radiation 
therapy  was  28.6%.  Sedlis  et  al.  reported  that  30  of  140  patients  died  without 
postoperative  radiation  therapy,  whereas  18  of137  patients  died  with  postoperative 
radiation  therapy.  These  findings  indicate  that  postoperative  radiation  therapy  has  a 
significant influence on the prognosis of uterine cervical carcinoma treated with radical 
hysterectomy. On the other hand, Thomas  et al. reported that postoperative radiation 
therapy had no significant impact on patients with lymph node metastasis because these 
patients  often  relapsed  from distant  sites.  However,  it  is  reported  that  postoperative 
radiation therapy was  useful for patients even with lymph node metastasis.In the current 
study, lymph node metastases  was recognized as a prognostic factor for all patients with 
stage IIB. Other prognostic factors for all patients of the current study were tumor size 
and surgical margin. It was obvious for surgical margin status to reflect the prognosis 
because of cancer cells left after treatment.
               Clinicians have been investigating the use of concurrent chemoradiation  in 
locally  advanced  cancer  cervix  for  many  years.  The Gynaecologic  Oncology Group 
(GOG) has been investigating the role of concurrent chemoradiation in cancer cervix 
since the early 70’s. The early studies concentrated on Hydroxyurea a drug used as a 
radiation sensitizer.  The effectiveness of  Cisplatin in producing tumour regression is 
patients with local recurrence or distant metastasis after primary treatment paved the 
way for its use in combination with radiation at an earlier stage of treatment. From 1979 
patients with locally advanced cancer cervix started receiving treatment with concurrent 
Cisplatin based chemoradiation. The overall 5 year survival of the study conducted by 
Blake et al.  was 49% for all stages. A complete remission rate of 89% was observed for 
stage III disease. This study suggested that Cisplatin based chemotherapy combined with 
radiotherapy could be safely used to treat cancer cervix patients at high risk or relapse. 
Around the same time a number of studies on Cisplatin based concurrent chemoradiation 
in cancer cervix were published.  Potish et al. and Twiggs et al. administered Cisplatin 
weekly in an effort to increase the percentage of radiation fractions given in proximity to 
the drug.  The starting dose was 10mg/m2 gradually escalating to 20mg/m2.  Both the 
regimes were well tolerated and the results were promising. Uncontrolled phase II trials 
in  concurrent  chemoradiation with single  agent  Cisplatin  in  locally  advanced cancer 
cervix  were  conducted  by  Wong  et  al.   (dose  25mg/m2  weekly),  Micheletti  et  al. 
(dose3mg/m2/day)  and  Malfateno  et  al. (dose  1mg/kg/wk).  The  results  of  all  these 
studies showed an improved local control rate with concurrent chemoradiation.
 Fields  et  al. and  Runowicz  et  al. conducted  phase  II  trials  of  concurrent 
chemoradiation using Cis-Platin (Dose: 20mg/m2 day 1 – 5 at 21 day intervals). The data 
revealed better disease free survival and overall survival for Cis-platin based regimen.
Souhami et al. conducted a phase II prospective trial of 50 patients with locally 
advanced cancer cervix patients stage II A – IV A treated with concurrent chemoradiation 
30 mg/m2 weekly on day 1 of every week. The total dose to point A was 75 Gy. A 
complete  response  rate  88% was  seen.  The  survival  rate  at  4  years  was  65% with 
acceptable toxicity.
Perez et al., Pignata et al., Meder et al.  and Rose et al. in their trials have proven 
the benefits of concomitant chemo-radiotherapy for locally advanced cancer cervix .
The  next  5  years  (1992-97)  proved  to  be  path  breaking  in  cervical  cancer 
treatment with concurrent chemoradiation. Five separate prospective randomized trials 
conducted  in  this  period  have  provided  compelling  evidence  that  the  addition  of 
concurrent Cisplatin containing chemotherapy to radiation improves the local control 
and long term survival  in patients with locally  advanced cancer cervix.  All  of  these 
studies were heterogeneous in that they differed with respect to inclusion criteria and 
treatment modalities. However each study demonstrated a reduction in the relative risk 
of recurrence by 30-50% in the arm containing Cisplatin.
                 Gilani  et al., conducted a trial using  concurrent cisplatin and external 
radiotherapy  prior to radical hysterectomy and lymphadenectomy in patients with stage 
IB-IIB  cervical  cancer.  The   analysis  of  the  surgical  specimens  revealed  complete 
pathological response in 43.3% of the cases and partial pathological response in 56.7% 
of patients. According to them the degree of pathological response was not predictable 
by the degree of clinical response. They have reported that 66.3% of patients showed 
thirty months disease-free survival and 77.31%, overall survival. Patients with complete 
and partial pathological response were not significantly different in terms of disease-free 
survival  (p=  0.08)  and  overall  survival  (p=  0.3).  Cisplatin  in  preoperative 
chemoradiation  is  effective  and  usually  well  tolerated  in  bulky  cervical  cancer  and 
parametrial  invasion,  inducing  a  high  rate  of  clinical  and  pathological  complete 
responses. When this therapy is followed by radical surgery, disease-free and overall 
survival rates are higher. 
                             Hall et al. and Peres et al. stated that the combined use of surgery and 
radiotherapy is associated with a complication rate higher than radiotherapy alone. A 
recent  randomized  study  conducted  by  Londoni  et  al. had  also  shown  a  higher 
complication rate in patients treated with the combined modality compared to that seen 
inpatients treated with surgery alone. Rouzier et al., performed a retrospective study to 
determine the incidence of residual disease in the hysterectomy specimens of patients 
with stage I & II B treated with primary radiotherapy or combined with chemotherapy 
and to identify patient or therapeutic factors associated with pathological response. They 
reported that pathologically confirmed residual disease on hysterectomy specimen is an 
independent factor of both local recurrence and over all survival. 
                                  The outcome of early cervical carcinoma treated by Wertheim  
hysterectomy with  selective  postoperative  radiotherapy  was studied  by  Tay  and Tan 
reported  that  Wertheim  hysterectomy  with  selective  postoperative  radiotherapy  for 
selected  high  risk  patients  was  an  effective  treatment  for  stage  IB  –IIA cervical 
carcinoma.
                       Morice et al. performed a  study to evaluate  prognostic factors and the 
role of  combination radiotherapy-surgery as treatment for patients with bulky stage Ib 
and II cervical carcinoma and opined that radical surgery combined with radiotherapy is 
feasible, with an acceptable rate of complications and yields satisfactory survival results 
in patients with bulky stage IB and II cervical carcinoma.
III. AIM OF THE STUDY
1. To evaluate the role of radical surgery in stage II B patients after 
external beam RT.
2. To establish surgery as an useful modality in prevention of late 
recurrences.
3. To avoid intracavity RT and its long term complications like 
adhesive vaginitis, bladder and rectal morbidities.
4. To improve local and regional control and possibly survival of the 
patient.
IV. MATERIALS AND METHODS
STUDY PERIOD: From March 2002 up to April 2007.
TYPE OF STUDY: Prospective non-randomized pilot study.
ELIGIBILITY CRITERIA: 
1. Patients with carcinoma cervix FIGO stage II B.
2.  Squamous cell carcinoma –Histology.
3. Patients with good performance status -1 (ECOG scales).
4. Patients with Co-morbidities like diabetes, hypertension also 
included after proper evaluation and control of their illness.
EXCLUSION CRITERIA: 
1. Any patients who has received treatment outside this institution (Radiotherapy or 
chemotherapy).
2. All other histologies except squamous cell carcinoma( All grades included).
3. Patients with either <or> stage II B.
4. Enlarged para-aortic nodes on CT scan.
STUDY PROTOCOL:
1. Informed consent obtained.
2. All patients undergo complete clinical evaluation including pelvic examination.
3. Staged according to FIGO ( UICC manual 2002).
4. Biochemical evaluation includes:
a. Complete hemogram
b. Urine analysis
c. Blood sugar, urea, Sr. creatinine
d. Blood grouping & typing
5. ECG
6.        Biopsy - Punch biopsy or slide review if biopsy done outside.
7. Radiology 
a. Chest X ray 
b. Ultrasound abdomen and pelvis 
c. Contrast enhanced CT scan of abdomen &pelvis.
8. Cystoscopy 
9.  Examination under Anesthesia:
          Done by two examiners of which one is a senior teaching faculty.
           FIGO staging done on EUA is  taken as final stage for treatment.
10. EBRT protocol
RT equipment CO-60 Phoenix for Teletherapy  
Dose details:
Total dose delivered : 50 Gy
Dose/# : 2Gy/#
Portals   :      AP & PA portals. Both portals treated daily
No of fractions :       25
Total duration            :      Usually 5-6 weeks(Not more than 6 weeks)
Treatment days / week :     5
Treatment planning   : EBRT
The whole pelvis including the cervix, vagina and parametria with the pelvic and 
iliac group of nodes was treated.
RT portal margins for EBRT
1. Superior: L4-L5  interspace  (to  include  all  the  iliac  and  hypogastric 
nodes).
2. Inferior: If  vagina  is  free  –  lower  margin  of  Obturator  foramen.  If 
vagina is involved – the entire vagina up to the introitus was 
included.
3. Lateral: 2cm lateral to bony pelvis.
11. Clinical reassessment : Assess for parametrial disease regression and   feasibility 
for surgery.
12. Type II  modified  radical hysterectomy at 4 to 6 weeks after surgery.
13. Recording of intraoperative and postoperative course and complications. 
14. Histopathological evaluation of specimen includes:
    a. Presence of residual tumor.
 b. Parametrial, vaginal margins.
   c. Evaluation of pelvic nodes.
15. Residual urine evaluation  with USG before discharge.
16. Follow-up
    Clinical examination every month  for 1st year
                                     every 2 months – 2nd  & 3rd year 
                                     every 3 months – 4 rd year 
                                     yearly – 5th year onwards
  CXR/USG and vaginal cytology annually
17.  Adjuvant treatment:
        For node positive patients only.
        Six cycles of cisplatin and 5FU.       
              After completing the radiation and surgery , the patients were reviewed  
every  month for the first one year followed by every 2 months for the next 2 years  
followed by once every 3 months thereafter for local recurrence and distal metastases 
with  clinical  and  radiological  assessment.  The  degree  of  pathologic  response  was 
assessed in the surgical specimens and lymph nodes. Complete pathological response 
(path  CR)  was  defined  as  either  a  tumor-free  specimen  or  just  a  few  microscopic 
scattered tumoral foci in the cervix which are not quantified. 
Statistical analysis
                  The Chi-Square test was used to evaluate the relationship between residual 
disease on surgical  specimen and clinico-pathologic  characteristics.  We used logistic 
regression model to analyze independent factors associated with residual disease. Local 
recurrence free survival  and over all  disease free survival  were calculated using the 
Kaplan-Meier method. We assessed the influence of clinical, pathologic and therapeutic 
factors on outcome in multivariate analysis using the Cox regression model.  Results 
with a  P value of<0.05 were regarded as statistically  significant.  Statistical  analyses 
were performed with SPSS version 9 .             
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                           V. OBSERVATIONS AND RESULTS
From March 2002 to April 2007 a total of 83 patients with previously untreated 
locally advanced cancer cervix IIB fulfilled the criteria for inclusion in this trial. Seven 
patients  were  excluded  because  they  defaulted  for  radiation  or  surgery.  The  median 
period of follow up was 24 months.
PATIENT CHARACTERISTICS 
In this study, we enrolled 39 (51.32%) patients belonging to the age group of ≤ 45 years 
and 37 (48.68%) patients belonging to the age group of >  45 years.  The median age of  
patients in this trial was 45 years. 
HISTOLOGICAL GRADE
Only squamous cell cancers were included in this trial. Of which 12 % of patients 
had  well  differentiated  squamous  cell  cancer,  78%  of  patients  had  moderately 
differentiated  squamous  cell  cancers  and    10% of  patients  in  the  trial  had  poorly 
differentiated squamous cell cancer.
 Forty-one (54%) had tumor size > 4cm and 35 (46%) had tumor size ≤4cm.
Patient's age
51%
49%
>45 years ≤45years 
Table 1. Patient characteristics
S.N
o Characteristics
Number of 
Patients(n) Percentage (%)
1
Patient’s age:
≤45 Years 39 51.32
>45 Years 37 48.68
2
Histological Grade:
Well Differentiated SCC 9 11.84
Moderately Differentiated 
SCC
59 77.63
Poorly Differentiated SCC 8 10.53
3
Tumor size:
>4cm 41 53.95
≤4cm 35 46.05
  
 
 
Histological grade
12%
77%
11%
Grade I
Grade II
GradeIII
Tumor size
54%
46% >4cm
<4cm
Table 2 . Pathological findings 
S.No. Characteristics Number  of 
patients(n)
Percentage(%)
1 Residual tumor 24 31.58
2 Vaginal margin 3 3.95
3 RT PM 1 1.32
4 LT PM - -
5  Positive  pelvic 
nodes
8 10.33
Pathological findings
24
3
1
0
8
0 5 10 15 20 25 30
Residual tumor
Vaginal margin
RT PM
LT PM
Pelvic node
Residual tumor was detected in 24 patients (32%) . Of these 3 patients (4%)  had 
positive  vaginal margin and one patient had positive  unilateral parametrium. Pelvic 
node  was positive  in 8 patients (10%).
Table 3. Postoperative complications 
S.No. Characteristics Number of Patients(n) Percentage(%)
1 Bladder morbidity 8 10.53
2 Wound infection 5 6.58
3 UV fistula 2 2.63
4 Incisional hernia 2 2.63
5 UTI 5 6.58
             
Postoperative complications
8
5
2
2
5
0 2 4 6 8 10
Bladder morbitity
Wound infection
Incisional hernia
UV fistula
UTI
       Mild to moderate  bladder morbidities  were seen in 8 patients (10%) (Table 3). Intra-
operative  complications  included  one  case  of  significant  bleeding.  Postoperative 
complications  included  two  cases  of  ureterovaginal  fistula  which  required  secondary 
stenting.  Long-term complications included two cases of incisional  herniae that  needed 
mesh repair .
Table 4.Outcome after radiotherapy and surgery 
S.No. Characteristics Number of Patients(n) Percentage (%)
1 Local recurrence 3 3.95
2 Distant metastasis 2 2.63
3 Mortality 1 1.32
32
1
0 1 2 3
Mortality
Distant metastasis
Local recurrence
Mortality,distant metastasis and local 
recurrence
Local recurrences were detected in three patients (3.95% ).There were two cases of distant  
metastasis: one to the lung, and one  to left supraclavicular nodes. One patient died as  a  
result  of progressive disease. 
Table 5. Survival after radiotherapy and surgery
S.No. Follow up duration (months)
Number of 
patients(n) Percentage(%)
1 <=12 24 31.58
2 13-24 18 23.68
3 >24 34 44.74
Follow up
32%
24%
44%
<=12
13-24
>24
  
       
  Median period of follow up was 24 months. Twenty four patients completed one year 
follow up. Eighteen patients completed two years follow up. All other patients falls in > 
24 months category. 
Table 6. Predictive factors of residual disease 
Parameter Number of 
patients(n)
Residual 
disease
Percentage(%) P Value
Histological 
Grade:
I 9 1 11.1
0.223II 59 19 32.2
III 8 4 50
Tumor size:
>4cm 41 17 41.5 <0.003≤4cm 35 7 20
Age:
≤45 years 39 15 38.46 0.185>45years 37 9 24.3
Incidence and predictive factors of residual disease:
                         Twenty four patients in this study had residual disease in the 
hysterectomy specimen. Incidence and predictive factors of residual disease are reported 
in Table 6 . Tumor size  was significantly correlated with  residual tumor.  Seventeen 
patients (41.5%) with  tumor size > 4cm  showed evidence of residual disease verses 
seven patients(20%)  with tumor size≤4cm ( P<0.003). Histological grade (P=0.223) and 
Age(P= 0.185) fell short of reaching statistical significance.  
Table 7. Predictive factors of nodal residue 
Parameter Number of 
patients(n)
Pelvic node Percentage(%) P Value
Histological 
Grade:
I 9 1 11
0.359
II 59 5 8.47
III
8 2 25
Tumor size:
>4 cm 41 5 12.1
0.323
≤4 cm
35 3 8.57
Age:
≤45 years 39 4 10.25
0.937>45 years
37 4 10.81
Incidence and predictive factors of nodal residue :
                The  predictive factors associated with nodal involvement with respect to the 
histological grade , tumor size, residual disease  and age  were reported to be statistically 
not significant . In the logistic regression model, the  tumor size (P <0.003) was an 
independent predictive  factor of residual disease in the hysterectomy specimen. 
Table 8. Predictive factors of  local recurrence 
Parameter Number 
of 
patients(n)
Local 
recurrence
Percentage(%) P Value
Histological 
Grade:
I 9 - - <0.005
II 59 1 1.69
III
8 2 25
Tumor size:
>4 cm 41 1 2.43
0.652
≤4 cm 35 2 5.71
Age:
≤45 years 39 2 5.12
0.587>45 years 37 1 2.7
Pelvic node:
Yes 8 2 25
<0.001No 68 1 1.4
Residual Tumor:
Yes 24 3 12.5
<0.009
   No 52 - -
Incidence and predictive factors of local recurrence: 
                   The histological grade (P = <0.005) ,  positive pelvic node
(P = <0.0001)and residual tumor (p = < 0.009) were significantly associated  with local 
recurrence. 
Table 9.Predictive factors of  distant metastasis
Parameter Number of 
patients(n)
Distant 
metastasis
Percentage (%) P Value
Histological 
Grade:
I 9 - -
0.743II 59 2 3.3
III 8 - -
Tumor size:
≤4cm 41 1 2.4
0.909>4cm 35 1 2.8
Age:
≤45years 39 1 2.5
0.570>45years 37 1 2.7
Pelvic node:
Yes 8 1 12.5
0.065
No 68 1 1.5
Residual 
tumor:
Yes 24 1 4.1 0.570
   No 52 1 1.9
Incidence and predictive factors of distant metastasis:
                   The predictive factors associated with distant metastases with respect to the 
histological grade, tumor size, residual disease, positive pelvic node and age were 
reported to be statistically not significant.
Table 10.Predictive factors of morbidity 
Parameter Number of 
patients(n)
Morbidity Percentage(%) P Value
Histological 
Grade:
I 9 1 11.11
0.70550II 59 13 22.33
III 8 1 12.5
Tumor size:
>4 cm 41 9 21.95
0.29127≤4 cm 35 6 17.14
Age:
<45 years 39 7 17.94
0.64620≥45years 37 8 21.62
Pelvic node:
Yes 8 2 25
0.76512No 68 9 13.23
Residual 
tumor:
Yes 24 4 16.66 0.71479
   No 52 11 21.15
Incidence and predictive factors of morbidity:
                          The  predictive factors associated with morbidities  with respect to the 
histological grade , tumor size, residual disease, positive pelvic node  and age  were 
reported to be statistically not significant.
Response:
Clinical response: All 76 patients were evaluated clinically  4 weeks after radiotherapy. 
Seventeen patients(22.36%) showed complete clinical response, and 59 (77.63%) partial 
clinical response. 
       Pathological response: Fifty two  out of 76 surgical specimens had no residual 
disease (68.42%).Twenty four patients(31.58%) had microscopic residual disease. Eight 
patients  had  positive  pelvic  nodes  in  surgical  specimens  (10.53%).One  patient  had 
parametrial involvement (1.33%) and three had vaginal margin positive in the pathology 
report (3.95%). There were two cases of distant metastasis: one to the lung, and one  to 
left supraclavicular nodes.
Survival:
After  a  median follow-up of  24  months  (range:1-  37  months),  overall  survival  was 
89.6% . Thirty-month survival for path CR was 88.89% and for path PR, 62.2%, which 
was not statistically significant (Fig. 1). Thirty-month disease-free survival was 66.3%.
Kaplan – Meier : Survival curve
Fig. 1. Overall survival rate
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VI. DISCUSSION
                        Invasive cervical cancer is the commonest cause of death from cancer  
among women in India. The constraints of the single modality treatment in achieving a 
“cure” forces us to venture into newer modalities of treatment to achieve this goal. The 
present study is an attempt to establish  the feasibility of new combined modality of 
treatment in stage IIB cervical cancer- radiation followed by radical surgery   to be an 
ideal treatment to achieve maximal benefit within the “window of curability”. 
          Lack of local control is a major cause of treatment failure in patients with bulky or 
advanced carcinoma  of the cervix. Several studies have confirmed that bulky cancer and 
extensive parametrial invasion are
poor prognostic features (Twiggs  et al., Wongs  et al. and Potish  et al. ). After a point 
dose of 85 Gy, pelvic failure rates  of 25-37% in bulky (> 4cm) stage Ib-IIa tumors,  and 
35-50% for stages IIb-III are considered standard results
           . Bulky tumors have significant level of hypoxic cell populations that are radio 
resistant.  This mechanism has been implicated as a major cause of treatment failure. 
The  radiation  doses  that  would  be  needed  to  overcome  the  radiation  resistance  of 
hypoxic populations may exceed the normal tolerance of the surrounding healthy tissues. 
Radical  surgery  could  play  a  role  in  this  scenario  by  eliminating  radio  resistant 
populations remaining after radiation.
         
  In  other  organs and other histological  types,(Peter  et  al.)  when chemotherapy and 
radiotherapy are followed by surgery, pathologic evaluation of residual disease has been 
demonstrated to provides precious information about tumor behavior and sensitivity to 
tailor adjuvant therapies. However, in most of the cervical cancer trials, hysterectomy 
was  not  included  in  the  treatment  schedule  or  was  performed  before  radiation  or 
chemoradiation.  It  has  been  reported  that  the  presence  of  residual  disease  in  the 
hysterectomy specimen may provide prognostic information, but surgery was limited to 
extrafascial hysterectomy with bilateral salpingo-oophorectomy in most of the studies 
and the series included a limited number of patients (Beskow et al.  and Calais  et al.). 
Moreover,  little  information  is  available  concerning  the  pathologic  assessment  of 
residual disease on hysterectomy specimen after chemoradiation. 
     This prospective non randomized study was performed to evaluate the role of radical 
surgery in stage II B patients after external beam RT and to establish surgery as an useful 
modality in prevention of late recurrences. We then assessed the impact of surgery on 
local control and survival of the patients.     
      Out of twenty four patients (31.5%) of the 76 patients with residual disease on the 
hysterectomy specimen only   four patients had metastatic pelvic lymph nodes. Factors 
significantly associated with lymph node involvement are reported in the Table-7. In the 
logistic regression model, tumor size is independent predictive factor of residual disease.
Residual disease and local control
                In our study, 31.5% of patients had residual disease on the hysterectomy 
specimen. In other studies, rates of residual disease on hysterectomy specimens after 
preoperative radiotherapy for cervical carcinoma have ranged from 21 to 78 %( Calais et  
al., Mauryama  et al., Moyses  et al., Mundt  et al.  and Keys  et al.). Factors associated 
with residual disease on hysterectomy specimens have been poorly studied. However, as 
residual disease is correlated with lower rates of local control; those factors may be used 
to  better  select  patients  who  may  benefit  from hysterectomy.  In  our  series,80%  of 
patients with tumors smaller than 4 cm displayed total eradication of their tumor by 
radiotherapy vs. 59% of patients with tumors 4cm or larger  ( P=<0.003).The correlation 
between size and the rate of residual cervical disease has been contradictorily reported in 
the literature. Beskow et al. found a significant effect of size, whereas Moyses et al. did 
not. Tumor grade may influence the presence of residual tumor on the hysterectomy 
specimen. In our series the histological grade (P=0.223) and age(P= 0.185) fell short of 
reaching statistical significance.
          There are obvious limitations in this prospective study design that must be 
acknowledged.  First,  during  the  study  period,  seven  patients  did  not  have  adjuvant 
surgery or preop radiation because of co morbidity or refusal. As they were not recorded 
prospectively in the database, we cannot provide further information concerning these 
patients. Keys et al.. have evaluated ,in a randomized clinical trial, the role of adjuvant 
hysterectomy after standardized radiation for patients with ‘bulky’ stage II B cervical 
cancer. In their study, there was a lower cumulative incidence of local relapse in the 
group  of  patients  that  had  adjuvant  hysterectomy  compared  to  the  radiation  only 
group(at 5years,27 vs. 14%).But there were no statistical difference in outcomes.
                In our study, the local recurrence rate of the patients treated with preoperative  
radiotherapy and radical surgery was 3.95%. Univariate analysis of various clinical and 
pathologic  factors  associated  with  local  control  and  survival  is  presented  in  Table-
8.Tumor  size,  residual  disease  on  hysterectomy  specimen,  and  pathological  nodal 
disease were significantly associated with local recurrence. In the multivariate analysis 
using Cox regression model,  the  data  pertaining to  tumor  size,  residual  disease  and 
pathologic node involvement were found to be independent predictive factors of local 
recurrence.
          The correlation between residual disease and nodal status also has been reported 
by Timmer  et al.  This correlation may be related to the selection of poor prognosis 
tumors which are less radiosensitive. But it also raises the question of metastasis seeding 
during the time interval between radiotherapy and surgery, explaining the weak impact 
of  hysterectomy on survival  in  previous publications(Gallion  et  al.,  Sundford  et  al., 
Perez et al., Keys et al., Resbeut et al .and Rotman et al.).
       The median duration of follow-up after  surgery was 24 months (range,  1–37 
months). Eight patients were lost to follow-up one month after the surgical procedure. 
Fig. 1 shows the survival curve. Disease recurred loco regionally in three patients, two 
patients  at  a  distant  sites  (Table  4).  Only  one  patient  (the  only  one  with  involved 
margins) had a massive pelvic recurrence that invaded the vagina, bladder, and lateral 
pelvic walls, 6 months after the surgical procedure. 
              Whether  performing  pelvic  surgery  in  patients  treated  with  primary 
radiotherapy continues to be debated. The use of surgery as adjuvant after preoperative 
radiation  or  chemoradiation  has  gained  acceptance  because  of  experience  in  the 
combined  treatment  of  rectal  and  other  malignancies  during  the  past  two  decades. 
Several retrospective analyses have compared patients who underwent hysterectomy or 
no pelvic surgery after radiotherapy (without concomitant chemotherapy) (Gallion et al.,  
Keys  et  al.  and  Resbeut  et  al.).  Only  one  randomized  trial  (closed  10  years  ago) 
comparing patients treated with initial external radiotherapy and randomly allocated to 
hysterectomy  (completion  pelvic  surgery)  versus  no  hysterectomy  (whatever  the 
presence of residual disease) has recently been published(Keys et al.). This study does 
not seem to demonstrate a benefit for overall survival. Nevertheless, a trend toward an 
increase in disease-free survival was observed in patients who underwent hysterectomy 
(62% vs.  53% at  5  years;  P =  .09).  The potential  advantages  of  hysterectomy after 
external radiotherapy are 2-fold: any residual disease can be removed with the prospect 
of  improving  (ideally)  event-free  survival,  and  the  nodal  status  can  be  adequately 
assessed, thus allowing adjuvant treatment in patients with nodal involvement. None of 
the published series has evaluated the value of hysterectomy after RT. In the randomized 
trial about  CRT conducted by Keys et al., hysterectomy was performed in both arms. 
The rate of  residual  disease after  CRT was lower compared with those treated with 
external radiotherapy  alone (48% vs. 59%; P = .04). In the case of patients without 
macroscopic residual disease confirmed at clinical examination and on MRI (8 weeks 
after the end of CRT), a randomized trial is ongoing in France to evaluate the effect of 
hysterectomy. Patients with a very small residuum (<1 cm) are probably in a situation 
similar to that of patients without residual disease; if the surgical procedure had been 
performed a few weeks later, this residuum would have been totally sterilized by CRT.    
  
       But in this study, after a median follow-up of 24 months (range: 1-37 months),  
overall survival was 89.6 %; 30 months survival for complete and partial pathological 
responders was 88.89% and 62.22%, respectively. Thirty months disease-free survival 
was 66.3%. 
             In the present series, 15 of 76 patients (19.73%) developed complications. The 
combined use of surgery and radiotherapy is associated with a complication rate higher 
than radical radiotherapy alone or chemoradiation. But our study had shown acceptable 
complication rate in patients treated with the combined modality compared to that seen 
in patients treated with radical radiotherapy alone or chemoradiation .
CONCLUSION
            Tumor size,  grade of  disease and positive  pelvic  node residue are  well 
recognized  prognostic  factors  which  influence  therapeutic  outcome  in  cancer  of  the 
cervix. The high failure rates seen in locally advanced cancer cervix with radiotherapy 
alone may be attributed to the presence of relatively radio-resistant hypoxic cells within 
the tumor mass. The following conclusions can be drawn from this preliminary phase III 
trial which showed the benefit of addition of surgery with radiation in stage IIB cervical 
cancer patients. Combined radiotherapy and radical surgery give the following benefits:
1. Pathologic evaluation of residual disease provides precious information about 
tumor behavior and sensitivity to tailor adjuvant therapies
2. Lesser complication rate compared with radical RT or chemoradiation 
3. Better local control and disease free survival  
In the current study, the use of radical surgery 4 weeks after completion of EBRT 
with  the  dose  of  50  Gy  had  shown  an  increased  locoregional  control   which  was 
demonstrated with statistically significant values. This radical surgery not only shown 
added benefit in the treatment of stage II B disease but also increased the local control 
with acceptable complications. The benefits are more pronounced in 
1. Young  patients 
2. Tumor size ≤ 4 cm size
3. Pelvic node negative  patients
The patients are on regular follow up for accrual of long term results. The impact 
of this study on long term survival as well as the long term morbidity associated with 
this protocol are to be analyzed in the future with a larger sample size in a randomized 
study.
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MASTER CHART
A B C D E F G H I J K L M N O P Q R S T
1 Sajeevamma
4
7 747/06 2 2 1 0 0 0 0 0 0 0 0 0 0 8 0 0
2 Thayammal
5
5 16/06 2 2 0 0 0 0 0 0 0 1 0 0 0
1
3 0 0
3 Andal
5
0 389/02 1 1 0 0 0 0 0 0 0 1 0 1 0
4
8 0 0
4 Alice
3
5 1146/05 2 1 1 0 0 0 0 0 0 0 0 0 0
1
4 0 0
5 Vasanthi
3
5 1000/06 2 1 0 0 0 0 0 0 1 0 0 0 0 6 0 0
6 Vasantha
4
2 127/05 3 2 0 0 0 0 0 0 0 0 0 0 0
2
4 0 0
7 Dhanalakshmi
4
8 761/06 2 1 0 0 0 0 0 0 0 1 0 0 0 8 0 0
8 Kanchana
3
5 519/05 1 1 0 0 0 0 0 0 0 0 0 0 0
2
0 0 0
9 Rajeswari
4
3 677/06 2 2 1 0 0 0 0 0 0 0 0 0 0 8 0 0
10 Adilaksmi
4
5 379/05 2 1 1 0 0 0 0 0 0 0 0 0 0
2
4 0 0
11 Latha
2
5 942/05 1 1 0 0 0 0 0 0 0 0 0 0 0
2
1 0 0
12 Ananathavalli
6
2 11168/05 3 1 1 0 0 0 1 0 0 0 0 0 0
1
5 1 0
13 Chinnaponnu
5
5 1283/04 2 1 0 0 0 0 0 0 0 0 0 0 0
2
7 0 0
14 Lakshmi
5
5 856/04 2 1 1 0 0 0 0 0 1 0 0 0 0
3
0 0 0
15 Santhi
4
0 66/06 2 1 0 0 0 0 0 0 0 0 0 0 0
1
5 0 0
16 Nagammal
5
0 29/07 2 2 0 0 0 0 0 0 0 0 0 0 0 2 0 0
17 Dhanalakshmi
3
5 1258/06 3 2 0 0 0 0 1 1 0 0 0 0 0 6 0 0
18 Muniamma
5
2 118/04 2 2 1 1 0 0 1 0 0 0 0 0 0 - 0 1
19 Seetha
4
0 141/04 2 2 1 0 0 0 0 0 0 0 0 0 0
3
9 0 0
20 Nagammal
4
5 1250/06 2 1 0 0 0 0 0 0 0 0 0 0 0 7 0 0
21 Padmavathi
6
4 1151/06 2 1 0 0 0 0 0 0 0 0 0 0 0 8 0 0
22 Lakshmi
4
0 1297/06 2 1 0 0 0 0 0 0 0 0 0 0 0 6 0 1
23 Valarmathi
4
0 62/07 2 1 0 0 0 0 0 0 0 0 0 0 0 3 0 0
24 Parvathi
4
8 1136/06 1 2 0 0 0 0 0 0 0 0 0 0 0 4 0 0
25 Sornammal
4
3 148/07 3 1 0 0 0 0 0 0 0 0 0 0 0 3 0 0
26 Sarojiniamma
4
5 78/06 2 2 1 0 0 0 0 0 0 0 0 0 0
1
4 0 0
27 Padmavathi
3
1 756/06 2 1 0 0 0 0 0 0 1 0 0 0 0
4
1 0 0
28 Pushpa
4
4 924/06 2 2 0 0 0 0 0 0 0 0 0 0 0
1
7 0 0
29 Pachayammal
5
0 678/06 2 1 0 0 0 0 0 0 0 0 0 0 0 11 0 0
30 Dhanalakshmi
4
2 284/02 2 2 1 0 0 0 0 0 0 0 0 0 0
4
1 0 0
31 Guna ammal
4
7 875/02 2 2 0 0 0 0 0 0 0 0 0 0 0
3
6 0 0
32 Vasanrha
4
0 710/02 2 2 1 0 0 0 0 0 0 0 0 0 0
3
9 0 0
33 Thankammal
5
4 374/06 1 2 1 0 0 0 0 0 0 0 0 0 0 8 0 0
34 Valliammal
5
5 780/06 2 1 0 0 0 0 0 0 0 0 0 0 0 8 0 0
35 Nagammal
7
8 318/05 2 2 1 1 0 0 0 0 0 0 0 0 0
2
4 0 0
36 Dhanalakshmi
5
5 529/06 2 2 0 0 0 0 0 0 0 0 0 0 0
1
0 0 0
37 Palaniammal
6
0 593/04 1 2 0 0 0 0 0 0 0 0 0 0 0
3
2 0 0
38 Gangai
4
5 996/04 2 2 1 1 0 0 0 0 0 0 0 0 0
2
9 0 0
39 Asirvatham
6
5 1471/04 2 1 0 0 0 0 0 0 0 0 0 0 0
2
9 0 0
40 Adilakshmi
6
0 1383/04 2 2 1 0 0 0 1 0 0 0 0 0 0
1
9 0 0
41 Sulochana
5
5 1334/04 2 1 0 0 0 0 0 0 0 1 0 1 0
2
7 0 0
42 Kani
4
5 1245/06 2 1 0 0 0 0 0 0 1 1 0 0 0
2
6 0 0
43 Mary
3
0 417/03 2 1 1 0 0 0 1 0 0 0 0 0 0
1
2 1 0
44 Muniamma
4
5 970/03 1 1 0 0 0 0 1 0 0 0 0 0 0
3
6 0 0
45 Kasthuri
4
9 1187/03 2 2 0 0 0 0 0 0 1 0 0 0 0
3
6 0 0
46 Lakshmi
5
0 2338/03 2 1 0 0 0 0 0 0 0 0 0 0 0
3
6 0 0
47 Rani
4
2 1164/05 2 1 0 0 0 0 0 0 0 0 0 0 0
2
4 0 0
48 Ponnamma
5
0 765/02 2 1 0 0 0 0 0 0 0 0 0 0 0
3
6 0 0
49 Pencilamma
4
5 189/03 2 1 0 0 0 0 0 0 0 0 0 0 0
3
6 0 0
50 Dhanalakshmi
4
8 216/03 2 2 1 0 0 0 0 0 0 0 0 0 0
3
6 0 0
51 Rani
4
0 236/03 3 2 1 0 0 0 0 0 0 0 0 0 0
2
4 0 0
52 Sowrajamma
5
4 589/01 2 2 0 0 0 0 0 0 0 0 0 0 0
4
8 0 0
53 Lakshmi
6
3 406/02 3 2 0 0 0 0 0 0 0 0 0 0 0
4
8 0 0
54 Umayal
5
0 213/02 2 1 0 0 0 0 0 0 0 0 0 0 0
4
8 0 0
55 Fathima Mary
4
9 1357/03 2 2 0 0 0 0 0 0 0 0 0 0 0
3
6 0 0
56 Guna Bhusanam
5
7 433/03 2 1 0 0 0 0 0 0 1 0 0 0 0
3
6 0 0
57 Alamelu
5
5 274/05 1 1 0 0 0 0 0 0 0 0 0 0 0
3
0 0 0
58 Salomi
3
8 370/05 2 1 0 0 0 0 0 0 0 0 0 0 0
2
4 0 0
59 Asmath
4
4 226/05 2 1 0 0 0 0 0 0 0 0 0 0 0
2
4 0 0
60 Lakshmi
5
5 1438/05 2 2 0 0 0 0 0 0 0 0 0 0 0
3
0 0 0
61 Ponnammal
4
5 1007/04 2 2 0 0 0 0 0 0 1 0 0 0 0
3
2 0 0
62 Saratha
3
5 675/04 2 1 1 0 0 0 0 0 0 0 0 0 0
3
0 0 0
63 Muniammal
5
2 1512/04 2 1 0 0 0 0 0 0 0 0 0 0 0
3
2 0 0
64 Pushpa
3
3 1064/04 1 2 0 0 0 0 0 0 0 0 0 0 0
3
3 0 0
65 Sasikala
3
0 606/02 3 1 1 0 0 0 0 0 0 0 0 0 0
1
2 0 0
66 Lakshmi
3
7 328/03 2 2 1 0 0 0 0 0 0 0 0 0 0
2
4 0 0
67 Vasantha
4
2 127/05 2 1 0 0 0 0 0 0 0 0 0 0 0
3
0 0 0
68 Seeniammal
4
2 1177/05 2 1 0 0 0 0 0 0 0 0 0 0 0
2
4 0 0
69 Kanthi
3
0 1154/05 3 2 1 0 0 0 0 0 0 0 0 0 0
1
2 1 0
70 Mallika
4
2 434/02 2 2 1 0 0 0 0 0 0 0 1 0 0
3
2 0 0
71 Ambujam
5
0 960/04 2 1 0 0 0 0 0 0 0 0 0 0 0
3
6 0 0
72 Karpagam
4
6 508/02 2 2 0 0 0 0 1 0 0 0 0 0 0
3
6 0 0
73 Varalakshmi
4
5 774/03 2 2 0 0 1 0 1 0 0 0 0 0 0 6 0 0
74 Gowri
5
3 682/02 2 2 1 0 0 0 0 0 1 0 0 0 1
1
2 0 0
75 Devaki
3
4 334/05 2 1 0 0 0 0 0 0 0 0 0 0 0
2
4 0 0
76 Sathyavathi
6
5 910/03 2 1 0 0 0 0 0 0 0 0 0 0 0 6 0 0
     
A-Serial No.  B-Name C-Age D-C.D.No.  E-Histological grade F-Tumor size  
G - Residual Tumor H-Vaginal margin   I-Right  parametrium    J-Left parametrium   
K-Pelvic nodal residue L-Mortality M-Bladder morbidity   N-Wound infection  
O-Uretero vaginal fistula  P-Incisional herenia   Q-UTI    R-Follow up(Months)  
S-Local recurrence T-Distant Metastasis     0-No 1-Yes    Tumor size: 0- ≤4 & 1- >4
